KOD
Price
$4.45
Change
-$0.29 (-6.12%)
Updated
Feb 21 closing price
Capitalization
234.18M
32 days until earnings call
VYNE
Price
$2.74
Change
+$0.04 (+1.48%)
Updated
Feb 21 closing price
Capitalization
40.42M
Ad is loading...

KOD vs VYNE

Header iconKOD vs VYNE Comparison
Open Charts KOD vs VYNEBanner chart's image
Kodiak Sciences
Price$4.45
Change-$0.29 (-6.12%)
Volume$224.66K
Capitalization234.18M
VYNE Therapeutics
Price$2.74
Change+$0.04 (+1.48%)
Volume$67.72K
Capitalization40.42M
KOD vs VYNE Comparison Chart
Loading...
KOD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KOD vs. VYNE commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KOD is a Hold and VYNE is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (KOD: $4.45 vs. VYNE: $2.74)
Brand notoriety: KOD and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KOD: 56% vs. VYNE: 57%
Market capitalization -- KOD: $234.18M vs. VYNE: $40.42M
KOD [@Biotechnology] is valued at $234.18M. VYNE’s [@Biotechnology] market capitalization is $40.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KOD’s FA Score shows that 1 FA rating(s) are green whileVYNE’s FA Score has 1 green FA rating(s).

  • KOD’s FA Score: 1 green, 4 red.
  • VYNE’s FA Score: 1 green, 4 red.
According to our system of comparison, VYNE is a better buy in the long-term than KOD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KOD’s TA Score shows that 4 TA indicator(s) are bullish while VYNE’s TA Score has 3 bullish TA indicator(s).

  • KOD’s TA Score: 4 bullish, 4 bearish.
  • VYNE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, KOD is a better buy in the short-term than VYNE.

Price Growth

KOD (@Biotechnology) experienced а -15.40% price change this week, while VYNE (@Biotechnology) price change was +10.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

KOD is expected to report earnings on May 14, 2025.

VYNE is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KOD($234M) has a higher market cap than VYNE($40.4M). VYNE YTD gains are higher at: -18.209 vs. KOD (-55.276). VYNE has higher annual earnings (EBITDA): -37.7M vs. KOD (-164.93M). KOD has more cash in the bank: 198M vs. VYNE (70.2M). VYNE has less debt than KOD: VYNE (123K) vs KOD (73.4M). VYNE has higher revenues than KOD: VYNE (493K) vs KOD (0).
KODVYNEKOD / VYNE
Capitalization234M40.4M579%
EBITDA-164.93M-37.7M437%
Gain YTD-55.276-18.209304%
P/E RatioN/A0.83-
Revenue0493K-
Total Cash198M70.2M282%
Total Debt73.4M123K59,675%
FUNDAMENTALS RATINGS
KOD vs VYNE: Fundamental Ratings
KOD
VYNE
OUTLOOK RATING
1..100
5410
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6545
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KOD's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for VYNE (59) in the Pharmaceuticals Major industry. This means that KOD’s stock grew somewhat faster than VYNE’s over the last 12 months.

KOD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VYNE (100) in the Pharmaceuticals Major industry. This means that KOD’s stock grew similarly to VYNE’s over the last 12 months.

KOD's SMR Rating (98) in the Biotechnology industry is in the same range as VYNE (98) in the Pharmaceuticals Major industry. This means that KOD’s stock grew similarly to VYNE’s over the last 12 months.

VYNE's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as KOD (65) in the Biotechnology industry. This means that VYNE’s stock grew similarly to KOD’s over the last 12 months.

VYNE's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for KOD (100) in the Biotechnology industry. This means that VYNE’s stock grew significantly faster than KOD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KODVYNE
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
N/A
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Ad is loading...
KOD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FLO19.400.33
+1.73%
Flowers Foods
SPH21.80-0.19
-0.86%
Suburban Propane Partners L P
WOW4.79-0.12
-2.44%
WideOpenWest
CYTH0.91-0.04
-4.03%
Cyclo Therapeutics
MFC30.36-1.46
-4.59%
Manulife Financial Corp

KOD and

Correlation & Price change

A.I.dvisor indicates that over the last year, KOD has been loosely correlated with BOLD. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KOD jumps, then BOLD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KOD
1D Price
Change %
KOD100%
-6.12%
BOLD - KOD
43%
Loosely correlated
-2.00%
AKBA - KOD
43%
Loosely correlated
-5.76%
IMNM - KOD
41%
Loosely correlated
-5.84%
RCKT - KOD
37%
Loosely correlated
-3.68%
ABOS - KOD
37%
Loosely correlated
+0.72%
More